Effect of oral gavage dosing regimens in female Tg rasH2 transgenic mice

被引:1
|
作者
Morton, D [1 ]
Sellers, RS [1 ]
Furst, SM [1 ]
Hawley, KD [1 ]
May, JR [1 ]
机构
[1] Pfizer Drug Safety Evaluat, Skokie, IL USA
关键词
carcinogenicity; gavage; mouse; sodium dodecyl sulfate; Tg rasH2; thymus; transgenic;
D O I
10.1080/01926230490457567
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Female Tg rasH2 (CB6F1/Jic-TgrasH2@ Tac) mice were administered water once daily, water twice daily with 8 or 12 hours between doses, 1% sodium dodecyl sulfate in water (1% SDS) once daily, or 1% SDS twice daily with 12 hours between doses by oral gavage at volumes of 10 ml/kg/day for 28 or 29 consecutive days. A control group of mice received no treatment and no sham manipulation. There were no significant differences in body weight or food consumption between treated groups and untreated control mice. Mean weights of spleens, livers, and thymuses were lower than control values in most groups of mice subjected to gavage. Focal or multifocal loss of thymic cortical architecture was observed in 13 of 50 mice distributed among all groups (including naive controls), however only in one instance was this finding suggestive of a precursor to neoplasia. This study demonstrated that Tg rasH2 mice can tolerate once or twice daily gavage dosing with water or vehicle containing 1% SDS. Loss of thymic cortical architecture was a common incidental finding in female Tg rasH2 mice.
引用
收藏
页码:413 / 417
页数:5
相关论文
共 50 条
  • [1] Evaluation of Background Tumor Incidence in rasH2 Mice and Clinical Pathology Data from rasH2 Non-Transgenic and Transgenic Mice
    Bonnette, K.
    Morse, M.
    [J]. INTERNATIONAL JOURNAL OF TOXICOLOGY, 2015, 34 (01) : 79 - 79
  • [2] Historical database of spontaneous tumors in transgenic rasH2 mice
    Zahalka, E. A.
    Paranjpe, M.
    Wenk, M. L.
    [J]. TOXICOLOGY LETTERS, 2011, 205 : S245 - S245
  • [3] Use of rasH2 transgenic mice for carcinogenesis testing of medical implants
    Palazzi, Xavier
    Kergozien-Framery, Sylvie
    [J]. EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, 2009, 61 (05) : 433 - 441
  • [4] The Tg rasH2 mouse in cancer hazard identification
    Morton, D
    Alden, CL
    Roth, AJ
    Usui, T
    [J]. TOXICOLOGIC PATHOLOGY, 2002, 30 (01) : 139 - 146
  • [5] PCR method for genotyping and zygosity-testing of RasH2 transgenic mice
    Suemizu, H
    Kito-Maruyama, C
    Sotomaru, Y
    Ogura, T
    Hioki, K
    Ohnishi, Y
    Tamaoki, N
    [J]. EXPERIMENTAL ANIMALS, 2004, 53 (05) : 463 - 466
  • [6] Hematopoietic Proliferative Lesions in the Spleen of rasH2 Transgenic Mice Treated with MNU
    Long, Gerald G.
    Goodman, Dawn G.
    Credille, Kelly M.
    Mann, Peter C.
    Wilson, Jonathan M.
    Cardy, Richard
    [J]. TOXICOLOGIC PATHOLOGY, 2010, 38 (07) : 1026 - 1036
  • [7] Butylhydroxytoluene (BHT) increases susceptibility of transgenic rasH2 mice to lung carcinogenesis
    Umemura, T
    Kodama, Y
    Hioki, K
    Inoue, T
    Nomura, T
    Kurokawa, Y
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2001, 127 (10) : 583 - 590
  • [8] Butylhydroxytoluene (BHT) increases susceptibility of transgenic rasH2 mice to lung carcinogenesis
    Takashi Umemura
    Yukio Kodama
    Kyoji Hioki
    Tohru Inoue
    Tatsuji Nomura
    Yuji Kurokawa
    [J]. Journal of Cancer Research and Clinical Oncology, 2001, 127 : 583 - 590
  • [9] Carcinogenic susceptibility of rasH2 mice to troglitazone
    Meilan Jin
    Miwa Takahashi
    Mitsuyoshi Moto
    Masako Muguruma
    Kazumi Ito
    Kyoko Watanabe
    Yusuke Kenmochi
    Taichi Kono
    Keiji Hasumi
    Kunitoshi Mitsumori
    [J]. Archives of Toxicology, 2007, 81 : 883 - 894
  • [10] Carcinogenic susceptibility of rasH2 mice to troglitazone
    Jin, Meilan
    Takahashi, Miwa
    Moto, Mitsuyoshi
    Muguruma, Masako
    Ito, Kazumi
    Watanabe, Kyoko
    Kenmochi, Yusuke
    Kono, Taichi
    Hasumi, Keiji
    Mitsumori, Kunitoshi
    [J]. ARCHIVES OF TOXICOLOGY, 2007, 81 (12) : 883 - 894